GlassScriptPhysician profile
Amy M Miller
NPI 1205864519
$526,401.13
in general payments reported to CMS, 2019-2025
26 companies · $207K in 2025
The $207K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $29K · 2021: $43K · 2022: $73K · 2023: $40K · 2024: $31K · 2025: $207K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Honoraria: $66K · Consulting Fee: $32K · Travel and Lodging: $24K · Food and Beverage: $11K · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $144,820.00 |
| Honoraria | $65,850.00 |
| Consulting Fee | $31,640.00 |
| Travel and Lodging | $24,121.60 |
| Food and Beverage | $10,885.56 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $215,202.91 | 2020-2025 | Rocklatan, Rhopressa, Simbrinza |
| Aerie Pharmaceuticals, INC. | $140,035.36 | 2019-2021 | |
| Harrow Eye, LLC | $77,783.36 | 2024-2025 | Vevye |
| Allergan, INC. | $63,682.78 | 2019-2022 | |
| Abbvie INC. | $15,609.11 | 2022-2025 | |
| Glaukos Corporation | $11,377.31 | 2023-2025 | Travoprost Intraocular Implant - Idose, Idosetr, Istent Infinite |
| Bausch & Lomb Americas INC. | $1,301.43 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $329.74 | 2021-2023 | |
| Ivantis, INC | $244.22 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $202.33 | 2024-2025 | Tecnis Simplicity, Veritas Vision System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $130.58 | 2019-2021 | |
| Oyster Point Pharma, INC. | $104.37 | 2023-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $61.26 | 2019-2025 | |
| Thea Pharma INC. | $45.14 | 2024-2025 | Iyuzeh |
| Biotissue Holdings INC. | $34.48 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $31.94 | 2024 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $31.22 | 2022 | |
| Alimera Sciences, INC. | $30.13 | 2024 | Yutiq, Iluvien |
| Cepheid | $28.51 | 2024 | Genexpert |
| Ani Pharmaceuticals, INC. | $27.64 | 2024 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $25.63 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $20.99 | 2023 | |
| Horizon Therapeutics Plc | $19.73 | 2022 | |
| Shire North American Group INC | $16.69 | 2019 | |
| New World Medical,INC. | $12.16 | 2023 | |
| Kala Pharmaceuticals, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.